Discover
AXSM
Axsome Therapeutics, Inc.
240.66
2 x 224.25
2 x 258.04
bid
ask
-
4.11
1.68%
2 @ 04:13 AM
243.28 +2.62 (1.09%)
| Ytd | 31.77% | |
| 1y | 133.72% |
237.64
day range
247.64
96.09
52 week range
260.19
| Open | 244.77 | Prev Close | 244.77 | Low | 237.64 | High | 247.64 | Mkt Cap | 12.38B |
| Vol | 757.95K | Avg Vol | 898.99K | EPS | -3.73 | P/E | N/A | Forward P/E | 40.81 |
| Beta | 0.60 | Short Ratio | 4.99 | Inst. Own | 76.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 227.38 | 200-d Avg | 172.83 | 1yr Est | 276.47 |
AXSM News
forbes.com
Why Axsome Stock Has Doubled In Nine Months
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative
benzinga.com
Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol A
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
globenewswire.com
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention De
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu
benzinga.com
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300
TD Cowen analyst Joseph Thome maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises t
benzinga.com
Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data f
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
Axsome Therapeutics Resolves All Patent Litigation Related To Axsome's Product SUNOSI
Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in t